Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RAB4B-EGLN2 readthrough long non-coding RNA is a naturally occurring RNA transcript resulting from read-through transcription between the neighboring RAB4B (RAB4B, member of the RAS oncogene family) and EGLN2 (egl nine homolog 2) genes on chromosome 19. This readthrough transcript is a candidate for nonsense-mediated mRNA decay (NMD) and is therefore unlikely to produce a protein product. As a long non-coding RNA (lncRNA), it is not known to function as a receptor, enzyme, or other classical drug target. Some studies have associated this locus or related lncRNAs with hepatocellular carcinoma, but the biological function of this specific transcript remains unclear and largely uncharacterized. There are no known drugs targeting this molecule, no defined mechanisms of action, no established biomarkers, and no reported safety concerns specifically associated with RAB4B-EGLN2[1][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RAB4B-EGLN2 readthrough long non-coding RNA (RAB4B-EGLN2).